Standard BioTools grants equity to senior executive
STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received new equity awards as part of his compensation.
Rhea-AI Filing Summary
STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received new equity awards as part of his compensation. He was granted options to buy 612,240 shares of common stock at an exercise price of $0.9846 per share, expiring on March 20, 2036. These options vest over four years, with 1/16 of the underlying shares vesting on May 20, 2026 and the rest in equal quarterly installments, contingent on continued service. He also received 272,107 restricted stock units that follow the same four‑year vesting schedule, each RSU converting into one share of common stock upon vesting. Following the stock grant, his directly held common stock position is 1,032,281 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 884,347 shares
Grant/Award
2 txns
Insider
Mackay Sean
Role
SVP & Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 612,240 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 272,107 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to buy) — 612,240 contracts (Direct);
Common Stock — 1,032,281 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
- F2. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
Stock options granted: 612,240 options
Option exercise price: $0.9846 per share
Option expiration: March 20, 2036
+3 more
6 metrics
Stock options granted
612,240 options
Grant to Sean Mackay on March 20, 2026
Option exercise price
$0.9846 per share
Exercise price for 612,240 options
Option expiration
March 20, 2036
Expiration date of granted options
RSUs granted
272,107 RSUs
Restricted stock units granted March 20, 2026
RSU initial vest date
May 20, 2026
1/16 of RSUs vest on this date
Common shares after grant
1,032,281 shares
Direct common stock holdings after RSU award
Key Terms
restricted stock units, RSUs, Stock Option (Right to buy), exercise price, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units ("RSUs") that vest over four years"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"1/16 of the RSUs vesting on May 20, 2026"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (Right to buy) financial
"security_title: "Stock Option (Right to buy)""
exercise price financial
"conversion_or_exercise_price: "0.9846""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-03-20T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Sean Mackay receive from STANDARD BIOTOOLS (LAB)?
Sean Mackay received a grant of stock options and restricted stock units from STANDARD BIOTOOLS. The award includes 612,240 options to buy common shares and 272,107 restricted stock units, all structured as compensation rather than open-market purchases or sales.
How do Sean Mackay’s new restricted stock units at STANDARD BIOTOOLS (LAB) vest?
The 272,107 restricted stock units vest over four years. One-sixteenth vests on May 20, 2026, and the remaining units vest in equal quarterly installments afterward, provided Sean Mackay continues his service with STANDARD BIOTOOLS through each applicable vesting date.
What are the key terms of Sean Mackay’s new stock options at STANDARD BIOTOOLS (LAB)?
Sean Mackay’s stock options cover 612,240 shares of common stock at an exercise price of $0.9846 per share. They become exercisable 1/16 on May 20, 2026, with the balance vesting quarterly, and they expire on March 20, 2036, contingent on continued service.
Are Sean Mackay’s reported STANDARD BIOTOOLS (LAB) transactions open-market buys or compensation grants?
The reported transactions are compensation-related grants, not open-market buy or sell trades. Both the stock options and restricted stock units are coded as awards, with zero transaction price per share and vesting schedules tied to Sean Mackay’s continued service at the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
